Azerbaijan and Georgia represent two of the most strategically valuable emerging clinical research markets in Eurasia. Together, they offer fast recruitment, high-quality clinical staff, and regulatory environments increasingly aligned with international standards.
For global CROs, pharma, and biotech sponsors seeking new patient access and accelerated study timelines, the Caucasus region provides a powerful competitive advantage.
Running clinical trials across both Georgia and Azerbaijan offers sponsors:
Access to >14 million people across both markets
High recruitment performance across all major therapeutic areas
Fast regulatory and ethics timelines
Strong PI networks and motivated investigators
Reduced competition for patients compared to Western Europe
Operational redundancy to protect timelines
Together, Azerbaijan & Georgia create one of the most efficient and resilient regional strategies for global study expansion.
Azerbaijan is emerging as one of the most promising new markets for global clinical trials. Recent approvals of updated clinical research legislation have created a favorable, modernized regulatory climate aligned with international principles.
With a population of over 10 million, highly trained medical professionals, and strong patient demand for modern therapies, Azerbaijan offers exceptional growth potential for global sponsors and CROs.
New, modern clinical trial legislation
Recently introduced regulatory reforms align more closely with EU standards, enabling clearer pathways, predictable timelines, and improved oversight.
Large, diverse patient population
Azerbaijan’s patient pool is significantly larger than Georgia’s, offering powerful recruitment potential for both common and rare indications.
Highly qualified investigators
Many Azerbaijani clinicians are trained internationally and have strong motivation to participate in innovative research programs.
High medical need & patient openness
Patients actively seek access to advanced therapies and novel treatments not yet available locally, resulting in strong trial participation interest.
Modern hospitals and specialized centers
Baku’s medical infrastructure includes large tertiary hospitals with oncology, cardiology, neurology, endocrinology, infectious disease, and surgical units.
Azerbaijan represents a scalable, high-access, high-readiness environment for clinical research.
Over the past 15–20 years, Georgia has established itself as a trusted destination for international clinical research. With a strong ecosystem of ICH-GCP–compliant investigators, modern clinical facilities, and streamlined ethics/regulatory processes, Georgia consistently outperforms many Western countries on recruitment speed and data quality.
Longstanding clinical trial experience
Georgia has participated in global clinical research for nearly two decades, partnering with top-tier global CROs and sponsors.
Presence of multiple global CROs
Many international CROs operate locally or regionally in Georgia due to its reliability, predictable timelines, and strong performance.
High recruitment efficiency
Despite a small population (~3.7 million), Georgia routinely outperforms many European countries on patient recruitment per site.
Strong investigator engagement
Georgian investigators are known for high motivation, excellent protocol adherence, and strong patient relationships.
Modern clinical infrastructure
Leading hospitals in Tbilisi and Batumi provide advanced diagnostics, imaging, oncology centers, cardiology units, and specialized departments ideal for Phase II–IV trials.
In a recent global Phase II study across multiple countries:
Georgia enrolled 32 patients within 12 months,
while comparable sites across two European countries enrolled only 28 patients over 3 years.
This example demonstrates a pattern often observed in Georgia:
high investigator motivation + large untreated patient pools = rapid recruitment.
A Phase II oncology study comparing Georgia with Western Europe found that:
Georgian sites recruited 4× faster,
met their FPI and LPI targets ahead of schedule,
and achieved 100% retention with zero major protocol deviations.
These results reflect why global CROs repeatedly select Georgia as one of the strongest small-population clinical research markets in Eurasia.
The recruitment examples and performance insights described on this page are based on clinical trials previously managed by team members of Helixion Clinical. These figures represent historical observations from past studies and are provided for illustrative purposes only.